The Long Non-Coding RNA SNHG12 Functions as a Competing Endogenous RNA to Modulate the Progression of Cerebral Ischemia/Reperfusion Injury: Up-Regulation of Bcl-2 by Sponging miR-136-5p and Consecutive Activation of the PI3K/AKT Signaling Pathway

Hao Zhang,Yuan Liu,Meizhai Zeng,Gongfeng Peng,Bo Liu,Xiaoou Sun
DOI: https://doi.org/10.2139/ssrn.3697997
2020-01-01
SSRN Electronic Journal
Abstract:Increasing evidence has demonstrated that long non-coding RNAs (lncRNAs) play a critical role in a variety of biological processes. However, their functions in cerebral ischemia are still largely unknown. Through lncRNA array analysis of the rat focal cerebral ischemia/reperfusion model, we found that the small nucleolar RNA host gene 12 (SNHG12) is a new type of lncRNA induced by ischemia/reperfusion. Here, we show that the expression of SNHG12 was up-regulated in the brain tissue of mice exposed to middle cerebral artery occlusion/reperfusion (MCAO/R) and primary mouse cerebral cortex neurons treated with oxygen-glucose deprivation/reoxygenation (OGD/R). Mechanistically, SNHG12 knockdown resulted in larger infarct sizes and worse neurological scores in MCAO/R mice. Consistent with the in vivo results, SNHG12 up-regulation significantly increased the viability and prevented apoptosis of neurons cultured under OGD/R conditions. In addition, we found that SNHG12 acts as a competing endogenous RNA (ceRNA) with microRNA (miR)-136-5p, thereby regulating the inhibition of its endogenous target Bcl-2. Overexpression of miR-136-5p significantly inhibited cell proliferation and promoted cell apoptosis. Moreover, SNHG12 was proven to target miR-136-5p, increasing Bcl-2 expression, which finally led to the activation of PI3K/AKT signaling. In conclusion, we demonstrated that SNHG12 acts as a ceRNA of miR-136-5p, thereby targets and regulates the expression of Bcl-2, which attenuates cerebral ischemia/reperfusion injury via activation of the PI3K/AKT pathway. These findings reveal a new function of SNHG12. This knowledge helps to better understand the pathophysiology of ischemic stroke and may provide new treatment options for this disease.Funding Statement: This study was supported by the China Postdoctoral Science Foundation (2019M652826) and the National Natural Science Foundation of China (31601089). Declaration of Interests: There are no conflicts of interest to declare.Ethics Approval Statement: The experimental animal studies were approved by the Institutional Animal Care and Use Committee of Guangdong Pharmaceutical University.
What problem does this paper attempt to address?